
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update on Esophageal Dysfunction Due to Disordered Immunity and Infection: Expert Review</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>AGA Clinical Practice Update on Esophageal Dysfunction Due to Disordered Immunity and Infection: Expert Review</strong></summary>
            <div>
                <ul><li>Authors: Chanakyaram A. Reddy, Emily McGowan, Rena Yadlapati, and Kathryn Peterson</li><li>Journal: Clinical Gastroenterology and Hepatology</li><li>Publication Date: 2024</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What is the estimated relative risk of Eosinophilic Esophagitis (EoE) in patients with achalasia?</li><li>2. In Esophageal Lichen Planus (ELP), what histological finding is characteristic, and in what percentage of biopsies is it typically found?</li><li>3. What is the preferred first-line treatment and typical duration for Candida esophagitis according to available guidelines?</li><li>4. While both HSV and CMV can cause viral esophagitis, how do their typical endoscopic appearances differ?</li><li>5. What percentage of patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) test positive for ANCA?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Best Practice Advice Statements</strong></summary>
            <div>
                <ul><li>Summary of key clinical recommendations.</li></ul>
                
        <details>
            <summary><strong>BPA 1 &amp; 2: Awareness &amp; Suspicion</strong></summary>
            <div>
                <ul><li>- Be aware of esophageal manifestations of systemic immunologic/infectious diseases to ↓ diagnostic delay.</li><li>- Identify risks for inflammatory/infectious causes.</li><li>- If infection is found, assess for signs of systemic immunocompromise &amp; consult infectious disease experts.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>BPA 3: Refractory Symptoms</strong></summary>
            <div>
                <ul><li>- If symptoms persist after infectious esophagitis therapy, evaluate for refractory infection or other underlying causes of esophageal/immunologic dysfunction.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>BPA 4: EoE &amp; Motility</strong></summary>
            <div>
                <ul><li>- In EoE patients with persistent symptoms despite remission, be aware of potential motility disorders (e.g., achalasia) &amp; consider further evaluation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>BPA 5: Lymphocytic Esophagitis (LyE)</strong></summary>
            <div>
                <ul><li>- For patients with histologic/endoscopic features of LyE, consider treatment with PPIs, swallowed topical corticosteroids, and esophageal dilation as needed.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>BPA 6: Hypereosinophilia</strong></summary>
            <div>
                <ul><li>- In patients with esophageal symptoms &amp; AEC &gt;1500 cells/uL, work up non-EoE eosinophilic GI disease, HES, and EGPA.</li><li>- Consult allergy/immunology for guidance.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>BPA 7: Rheumatologic Diseases</strong></summary>
            <div>
                <ul><li>- In SSc, MCTD, SLE, or Sjogren’s, be aware that esophageal symptoms can occur from muscle layer involvement → dysmotility/LES incompetence.</li><li>- Dysfunction is often significant in SSc and MCTD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>BPA 8: Crohn&#x27;s Disease</strong></summary>
            <div>
                <ul><li>- A minority of Crohn&#x27;s patients can develop esophageal involvement (inflammatory, stricturing, fistulizing).</li><li>- Tends to occur in individuals with active intestinal disease.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>BPA 9: Dermatologic Diseases</strong></summary>
            <div>
                <ul><li>- In lichen planus or bullous disorders, dysphagia can occur from visible esophageal mucosal involvement.</li><li>- Esophageal lichen planus (ELP) can occur w/o skin involvement.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>BPA 10: Secondary Achalasia</strong></summary>
            <div>
                <ul><li>- During initial achalasia evaluation, consider infectious (COVID, Chagas) and inflammatory (eosinophilic disease) causes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Infectious Etiologies</strong></summary>
            <div>
                <ul><li>- Most common: Candida, Herpes Simplex Virus (HSV), Cytomegalovirus (CMV).</li><li>- Can occur in both immunosuppressed and immunocompetent hosts.</li></ul>
                
        <details>
            <summary><strong>Candida Esophagitis</strong></summary>
            <div>
                <ul><li>- Most common infectious esophagitis.</li><li>- Presents with dysphagia or odynophagia.</li></ul>
                
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- Endoscopy: White nummular lesions; may carpet the entire esophagus in severe cases.</li><li>- Histology: Cytobrush or biopsies identify fungal forms.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Risk Factors</strong></summary>
            <div>
                <ul><li>- Recent antibiotics.</li><li>- Local/systemic steroids or immunosuppression.</li><li>- Malignancy, PPI use, older age, chronic alcohol use, CKD, diabetes.</li><li>- Motility disorders → esophageal stasis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- Preferred: Fluconazole 200-400 mg/day for 14-21 days.</li><li>- Prophylaxis: Nystatin may be used for high-risk patients.</li><li>- Asymptomatic Cases: Treatment is unclear; one study showed asymptomatic candidiasis rarely becomes symptomatic.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Viral Esophagitis</strong></summary>
            <div>
                <ul><li>- Common presentation: Dysphagia or severe odynophagia.</li></ul>
                
        <details>
            <summary><strong>Herpes Simplex Virus (HSV)</strong></summary>
            <div>
                <ul><li>- Endoscopy: Multiple small, shallow, well-circumscribed ulcers.</li><li>- Histology: Intra-nuclear eosinophilic inclusions.</li><li>- Treatment: Acyclovir, valacyclovir, or famciclovir.</li><li>- Immunocompetent: Up to 10 days.</li><li>- Immunosuppressed: Up to 21 days.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cytomegalovirus (CMV)</strong></summary>
            <div>
                <ul><li>- Endoscopy: Few large, cratered ulcers.</li><li>- Histology: Large eosinophilic or basophilic intranuclear inclusions.</li><li>- Treatment: Ganciclovir or valganciclovir for up to 6 weeks.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HIV</strong></summary>
            <div>
                <ul><li>- Endoscopy: Can present with a few discrete esophageal ulcerations.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Immune Dysfunction of the Esophagus</strong></summary>
            <div>
                <ul><li>Esophageal symptoms can be a manifestation of immune dysfunction, either localized to the esophagus or as part of a systemic disease.</li></ul>
                
        <details>
            <summary><strong>Localized Immune Dysfunction</strong></summary>
            <div>
                <ul><li>Involves local immune responses within the esophagus.</li></ul>
                
        <details>
            <summary><strong>Eosinophilic Esophagitis (EoE)</strong></summary>
            <div>
                <ul><li>- Clinicopathologic condition: Esophageal dysfunction + ≥15 eosinophils/hpf.</li><li>- Trigger: Food or aeroallergens → Type-2 (allergic) response.</li></ul>
                
        <details>
            <summary><strong>Presentation &amp; Diagnosis</strong></summary>
            <div>
                <ul><li>- Symptoms: Vary by age; dysphagia, chest pain, food impactions.</li><li>- Endoscopy: Edema, rings, exudates, furrows, strictures; can appear normal.</li><li>- Biopsy Protocol: Multiple biopsies from ≥2 esophageal levels due to patchy inflammation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pathophysiology &amp; Complications</strong></summary>
            <div>
                <ul><li>- Untreated inflammation → transmural remodeling, smooth muscle hypertrophy.</li><li>- Result: ↓ esophageal wall compliance &amp; contractility.</li><li>- Motility Issues: Persistent symptoms despite remission may signal subtle strictures or motility disorders.</li><li>- Achalasia Risk: ↑ risk for achalasia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- Diet: Elimination diets.</li><li>- Medical: PPIs, swallowed topical corticosteroids (Budesonide oral suspension is FDA-approved).</li><li>- Biologic: Dupilumab (anti-IL-4 receptor alpha antibody) is FDA-approved.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Lymphocytic Esophagitis (LyE)</strong></summary>
            <div>
                <ul><li>- Histology: Dense peripapillary lymphocytic infiltrate &amp; spongiosis w/o significant eosinophils/neutrophils.</li><li>- Prevalence: ≈0.1% in a large biopsy series.</li></ul>
                
        <details>
            <summary><strong>Clinical Features</strong></summary>
            <div>
                <ul><li>- Demographics: Mostly women &gt; 60 years old.</li><li>- Symptoms: Dysphagia in ≈2/3 of patients.</li><li>- Endoscopy: Abnormal in ≈70-75%; rings, esophagitis, stricture are most common.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis &amp; Treatment</strong></summary>
            <div>
                <ul><li>- Diagnosis: Must rule out EoE-like disease (biopsy off PPI for 2-4 weeks) and Crohn&#x27;s disease.</li><li>- Treatment: PPI therapy, swallowed topical corticosteroids, esophageal dilation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Systemic Inflammation Manifestations</strong></summary>
            <div>
                <ul><li>Esophageal dysfunction as part of a systemic inflammatory or autoimmune process.</li></ul>
                
        <details>
            <summary><strong>Hypereosinophilic Syndromes (HES)</strong></summary>
            <div>
                <ul><li>- Definition: AEC &gt;1500 cells/uL + organ damage from eosinophilic infiltration.</li><li>- GI Involvement: Up to 38% of HES patients have GI symptoms; can mimic EoE.</li><li>- Distinguishing Feature: HES has peripheral hypereosinophilia, rare in isolated EoE.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Eosinophilic Granulomatosis w/ Polyangiitis (EGPA)</strong></summary>
            <div>
                <ul><li>- Definition: Rare systemic eosinophilic vasculitis of small-medium arteries (formerly Churg-Strauss).</li><li>- ANCA Status: Positive in only 30-40% of patients.</li><li>- Esophageal Involvement: Rare; due to eosinophilic infiltration or vasculitic neuropathy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Autoimmune Diseases</strong></summary>
            <div>
                <ul><li>Esophageal involvement in various rheumatologic conditions.</li></ul>
                
        <details>
            <summary><strong>Crohn&#x27;s Disease</strong></summary>
            <div>
                <ul><li>- Uncommon in adults; more frequent in children (20% in one study).</li><li>- Features: Superficial/deep ulcers, often with active disease elsewhere.</li><li>- Treatment: Requires biologic therapy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Scleroderma (SSc) &amp; MCTD</strong></summary>
            <div>
                <ul><li>- SSc: Atrophy/fibrosis of smooth muscle → severe hypomotility &amp; incompetent LES.</li><li>- MCTD: Resembles SSc but can affect both striated (proximal) and smooth (distal) muscle; may be less severe.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Sjogren&#x27;s &amp; SLE</strong></summary>
            <div>
                <ul><li>- Sjogren&#x27;s: Up to 80% of patients complain of dysphagia.</li><li>- SLE: Dysphagia from dysmotility with unclear mechanism.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Myositis</strong></summary>
            <div>
                <ul><li>- Conditions: Polymyositis, dermatomyositis, inclusion body myositis.</li><li>- Involvement: Affects proximal striated muscle, especially cricopharyngeus (CP).</li><li>- Prevalence: 30-80% experience dysphagia.</li><li>- Management: CP-directed therapy (dilation, botulinum toxin, myotomy).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Dermatologic Diseases</strong></summary>
            <div>
                <ul><li>Esophageal involvement can occur even without skin manifestations.</li></ul>
                
        <details>
            <summary><strong>Pemphigus Vulgaris (PV)</strong></summary>
            <div>
                <ul><li>- Most common bullous disorder.</li><li>- Endoscopy: Non-specific findings (erythema, red longitudinal lines, erosions, blisters).</li><li>- Diagnosis: Direct immunofluorescence (DIF) is diagnostic (IgG &amp; C3 deposition).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Lichen Planus (LP)</strong></summary>
            <div>
                <ul><li>- Most common dermatologic disorder to affect the esophagus.</li><li>- Esophageal LP (ELP) can be isolated (33% of cases) and has a predilection for middle/older aged Caucasian females.</li></ul>
                
        <details>
            <summary><strong>Features &amp; Diagnosis</strong></summary>
            <div>
                <ul><li>- Endoscopy: Narrowed caliber (proximal/middle), strictures, pale/edematous mucosa, peeling/sloughing on contact, thick white exudates.</li><li>- Histology: Civatte bodies are characteristic but found in &lt;50% of biopsies.</li><li>- DIF: Not diagnostic, but fibrinogen deposition is suggestive.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Management &amp; Risks</strong></summary>
            <div>
                <ul><li>- Treatment: Swallowed topical corticosteroids (&gt;60% benefit); systemic immunosuppressants for non-responders.</li><li>- Cancer Risk: ↑ risk of esophageal squamous cell carcinoma.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Pearl (DIF)</strong></summary>
            <div>
                <ul><li>- For suspected dermatologic involvement, obtain biopsies for DIF from both involved and nearby uninvolved mucosa.</li><li>- Place samples on saline-soaked gauze for transport.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Achalasia: Immune &amp; Infectious Etiologies</strong></summary>
            <div>
                <ul><li>Recent evidence suggests infectious and immune-mediated pathways for some achalasia subsets, challenging the purely idiopathic view.</li></ul>
                
        <details>
            <summary><strong>Autoimmune Hypothesis</strong></summary>
            <div>
                <ul><li>- Theory: Autoimmune disease targeting esophageal myenteric neurons.</li><li>- Association: Patients with achalasia are more likely to have other autoimmune conditions (Sjogren&#x27;s, SLE, SSc).</li><li>- Risk: OR 1.26 to 3.6 for comorbid autoimmune disease.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Allergy-Mediated Association</strong></summary>
            <div>
                <ul><li>- Histology: Dense eosinophil accumulation found in the muscularis propria of achalasia patients.</li><li>- EoE Link: Strong association between EoE and achalasia.</li><li>- Relative Risk: Estimated RR of EoE in achalasia is 32.9 (95% CI, 24.8-42.8), higher in patients ≤40 years old.</li><li>- Mechanism: Eosinophils/mast cells release products that can cause motility disturbances or neuronal destruction.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Secondary Achalasia: Malignancy</strong></summary>
            <div>
                <ul><li>- Paraneoplastic phenomenon.</li><li>- Associated Cancers: Lymphoma, lung cancer, breast cancer, esophageal adenocarcinoma.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Secondary Achalasia: Infections</strong></summary>
            <div>
                <ul><li>Specific pathogens can trigger achalasia-like motility disorders.</li></ul>
                
        <details>
            <summary><strong>Chagas Disease (Trypanosoma cruzi)</strong></summary>
            <div>
                <ul><li>- Mechanism: Immune cross-reactivity between T. cruzi antigen and the myenteric plexus → neuronal degeneration.</li><li>- Result: Loss of peristalsis &amp; impaired LES relaxation.</li><li>- Prevalence: GI manifestations (megaesophagus) in 10-15% of chronically infected; ≈300,000 cases in the US.</li><li>- Diagnosis: Serologic tests.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Post-COVID-19 Infection</strong></summary>
            <div>
                <ul><li>- Mechanism: SARS-CoV-2 may trigger inflammation and ganglionic cell destruction via neuronal ACE2 receptors.</li><li>- Findings: ↑ viral proteins (N &amp; S) and inflammatory markers (NLRP3, TNF) in esophageal muscle of post-COVID achalasia patients.</li><li>- Management: Unclear if reversible; myotomy has shown favorable short-term outcomes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Considerations Summary</strong></summary>
            <div>
                <ul><li>A structured approach to diagnosis based on patient history and clinical context.</li></ul>
                
        <details>
            <summary><strong>History: Immunosuppression / Recent Antibiotics</strong></summary>
            <div>
                <ul><li>- Consider: Candidal esophagitis, HSV, CMV, medication-induced ulceration.</li><li>- Tests: Upper endoscopy with biopsies and brushings.</li><li>- Endoscopy: White nummular lesions (Candida); shallow ulcers (HSV); deep ulcer(s) (CMV); 1-2 well-marked ulcers (pill-induced).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>History: Atopy / Allergy</strong></summary>
            <div>
                <ul><li>- Consider: Eosinophilic Esophagitis (EoE).</li><li>- Tests: Upper endoscopy with biopsies from proximal &amp; distal esophagus (off PPI for 2-4 weeks).</li><li>- Endoscopy: Edema, rings, exudates, furrows, strictures; can appear normal.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>History: Autoimmune Disease (Crohn&#x27;s, SSc, SLE, Sjogren&#x27;s, Myositis)</strong></summary>
            <div>
                <ul><li>- Consider: Esophageal involvement of the systemic disease (inflammatory or dysmotility).</li><li>- Tests: Upper endoscopy with biopsies, high-resolution manometry.</li><li>- Findings: Varied; ulcerations (Crohn&#x27;s), absent contractility (SSc), non-specific edema/stenoses (Sjogren&#x27;s), cricopharyngeal issues (myositis).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>History: Dermatologic Disease (Bullous disorders, Lichen Planus)</strong></summary>
            <div>
                <ul><li>- Consider: Esophageal involvement of dermatologic disease.</li><li>- Tests: Upper endoscopy with biopsies for H&amp;E and DIF.</li><li>- Endoscopy (LP): Narrowed caliber, pale/edematous mucosa, peeling/sloughing, white exudates.</li><li>- Endoscopy (Pemphigus): Sloughing/blistering, erythema, red longitudinal lines.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>History: Recent COVID Infection / Travel to Central/South America</strong></summary>
            <div>
                <ul><li>- Consider: Post-COVID dysmotility/achalasia, Chagas disease.</li><li>- Tests: Upper endoscopy, high-resolution manometry, timed barium esophagram. Consider infectious disease consult for Chagas serology.</li><li>- Endoscopy: Often normal or shows chronic stasis changes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
